对于针对癌性厌食-恶病质治疗领域的美适亚产品，通过 一年多的推广，该产品今年前三季度销售收入已接近 1 亿元， 后续公司将结合国家医保国谈进展等，积极推进相关产品的推 广销售工作，进一步提升医院、医生和患者对产品的认知、认 可度。 证券代码：000661 证券简称：长春高新 长春高新技术产业（集团）股份有限公司 投资者关系活动记录表 编号：2025-006 | | □特定对象调研 □分析师会议 | | --- | --- | | □媒体采访 投资者关系活动 | □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | □现场参观 | ☑ 其他 电话会议 | | HBM | Partners Hong Kong Limited、巴道基金、宝盈基金、博裕资本、 博远基金、创金合信基金、重阳投资、鼎讯基金、东方医药、东方证 | | | 券、东海证券上海自营、东吴证券、方正富邦基金、工银瑞信基金、 | | | 广东正圆私募基金、广发基金、国海证券、国华兴益保险资管、国金 | | | 证券、国联安基金、国盛证券、国泰基金、海富通基金、泓德基金、 | | | 华泰证券、华泰证券（上海）资管、华西证券、华夏久盈资管 ...

Core Viewpoint - The Hang Seng Index closed at 26,050.08 points, down 0.89%, while the Hang Seng Tech Index fell by 1.91% to 5,936.39 points, indicating a bearish trend in the market [1] Group 1: Market Performance - The Hang Seng Index experienced a decline of 0.89% [1] - The Hang Seng Tech Index saw a decrease of 1.91% [1] Group 2: Sector Performance - Innovative drug concept stocks showed strong performance, with 3SBio rising over 10% and Innovent Biologics increasing nearly 7% [1] - Chip stocks generally fell, with Hua Hong Semiconductor dropping nearly 7%, SMIC declining over 5%, and Shanghai Fudan decreasing nearly 5% [1]

Group 1 - The Hang Seng Index fell by 0.89%, down 232 points, closing at 26,050 points, while the Hang Seng Tech Index dropped by 1.91% [1] - The early trading volume in Hong Kong stocks reached 142.3 billion HKD [1] - The Hang Seng Biotechnology Index rebounded by 2.16%, with notable gains in stocks such as InnoCare Pharma (up 10.88%) and 3SBio (up over 10%) [1] Group 2 - Fosen Pharmaceuticals surged nearly 74% during the session, with an early gain of 59.42% after the approval of Enzalutamide soft capsules and the potential selection of Metformin and Dapagliflozin for national procurement [1] - Rongchang Bio reported a 40% year-on-year increase in revenue for the first three quarters, with a significant reduction in losses, leading to a stock increase of 6.75% [2] - Spring Medical turned a profit in the third quarter, earning 77.06 million CNY, and saw its stock rise by over 21% as it actively expanded its international market [3] Group 3 - Newly listed stock Dipo Technology continued to rise, increasing by 18.97%, with its stock price doubling within three days of listing [4] - Ansteel Group's stock fell over 8%, with a net loss of 2.04 billion CNY for the first three quarters, although losses narrowed year-on-year [5] - Zoomlion Heavy Industry's stock rose over 3% after reporting a 24.89% year-on-year increase in net profit attributable to shareholders for the first three quarters, driven by its ongoing expansion in the mining machinery sector [5] Group 4 - China Everbright Bank's stock dropped by 5% following a decline in both revenue and profit for the first three quarters, facing pressure from fair value changes [5] - Huahao Zhongtian Pharmaceutical saw its stock drop over 37% due to a significant unlock of shares after one year of listing [6] - Lion King Holdings plummeted over 24% to a new low as it proposed to issue convertible bonds to raise approximately 260 million HKD for investments in gold and related products [7] - Air China experienced a drop of over 8%, with a more than 11% decline in net profit for the third quarter, and plans to raise no more than 20 billion CNY through A-share placement [8]

智通财经APP获悉，映恩生物-B(09606)盘中涨超13%，截至发稿，涨11.1%，报314.4港元，成交额5.73 亿港元。 消息面上，映恩生物此前公告称，公司董事会决议拟在科创板上市，该事项需视市场状况，并获董事会 进一步批准、股东大会批准及监管机构许可。据悉，今年4月15日，映恩生物在港交所主板正式挂牌， IPO募资总额超15亿港元，是近四年来港股18A板块募资规模最大的IPO之一。 国金证券发布研报称，快速的创新步伐刺激了ADC技术领域的大规模交易，公司已与全球多家行业领 先企业达成多项对外许可及合作协议，包括与BioNTech、百济神州、Adcendo、GSK及Avenzo， 2023/2024/2025上半年确认BD收入合计分别为17.81/19.37/12.27亿元，总交易价值超60亿美元。 ...

Core Insights - Shenzhen MicuRx Biotech Co., Ltd. reported a significant revenue growth of 40.12% year-on-year, reaching 674 million yuan in the first three quarters of 2025, with Q3 revenue at 268 million yuan, marking a 49.51% increase [1] - The net profit attributable to shareholders for Q3 was 41.1753 million yuan, while the net profit for the first three quarters was 70.7675 million yuan [1] - The growth in performance is primarily driven by increased sales of the products Sidabenan and Siglecatin, with Sidabenan sales up 18.76% and Siglecatin sales soaring by 136.13% year-on-year [1] Company Strategy - MicuRx is leveraging a global development strategy based on early research in China, assembling a team of top scientists with extensive experience in relevant fields [1] - The company employs an integrated technology platform that utilizes AI-assisted design and chemical genomics, facilitating the entire process from basic research to clinical translation [1] - MicuRx has successfully developed first-in-class and best-in-class innovative drugs, with two innovative drugs already marketed globally across multiple indications [1] Product Portfolio - The company has established a diverse pipeline of research projects with differentiated advantages and global competitiveness in five major areas: malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases, and antiviral treatments [1]

Core Points - The conference call is part of Invivyd's REVOLUTION Pivotal Program, indicating a significant development in their research and clinical activities [1] - Key speakers include Marc Elia, Dr. Robert Allen, Dr. Mark Wingertzahn, and Tim Lee, highlighting the involvement of senior leadership in the discussion [2] - The call will include forward-looking statements regarding research, regulatory plans, and corporate strategy, which are subject to various risks and uncertainties [3] Summary by Sections Company Overview - Invivyd is conducting a pivotal program, suggesting a focus on advancing their clinical development efforts [1] - The leadership team participating in the call includes the Chairman, Chief Scientific Officer, Senior VP of Clinical Development, and Chief Commercial Officer, indicating a comprehensive approach to the discussion [2] Research and Development - The discussion will cover research and development activities, emphasizing the company's commitment to innovation and future prospects [3] Regulatory and Commercial Strategy - Forward-looking statements will address regulatory plans and corporate strategy, reflecting the company's strategic direction and potential market positioning [3]

公告称，康希诺第三季度业绩的强劲增长，主要源于核心产品曼海欣的市场表现。曼海欣作为中国流脑 疫苗领域仅有的四价流脑结合疫苗产品，凭借其创新优势，展现出强劲的市场表现力，实现了市场占有 率的不断攀升，推动公司前三季度营收同比增长22.13%。 智通财经APP获悉，康希诺生物(06185)再涨超4%，截至发稿，涨3.84%，报45.98港元，成交额2551.36 万港元。 消息面上，康希诺生物发布业绩，第三季度实现营业收入3.10亿元，同比增长17.67%；归属于上市公司 股东的净利润2792.56万元，同比增长842.01%。前三季度实现营业收入6.93亿元，同比增长22.13%；归 属于上市公司股东的净利润1444.01万元，同比扭亏为盈。 ...

Group 1 - The core viewpoint of the news is that Kanghua Biological has seen a 5% increase in stock price, reaching 77.25 yuan per share, with a trading volume of 203 million yuan and a turnover rate of 2.24%, resulting in a total market capitalization of 10.038 billion yuan [1] - Kanghua Biological, established on April 2, 2004, and listed on June 16, 2020, is primarily engaged in the comprehensive research, development, and operation of vaccines, with 99.99% of its main business revenue coming from non-immunization planning vaccines [1] Group 2 - Among the top ten circulating shareholders of Kanghua Biological, a fund under Southern Fund holds a position. The Southern CSI 1000 ETF (512100) reduced its holdings by 11,100 shares in the third quarter, now holding 850,600 shares, which accounts for 0.72% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 76.63 billion yuan. Year-to-date returns are 27.12%, ranking 2130 out of 4216 in its category, while the one-year return is 25.9%, ranking 2007 out of 3889 [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 6 years and 360 days, managing total assets of 122.76 billion yuan, with the best fund return during the tenure being 182.39% and the worst being -15.93% [2]

Core Insights - Cloudy New Horizon has entered into an exclusive licensing agreement with Visara, Inc. for the development, production, and commercialization of the dual-action biopharmaceutical VIS-101 in Greater China, Singapore, South Korea, and several Southeast Asian countries [1] Group 1: Product Development - VIS-101 targets VEGF-A and ANG-2, showing significantly improved efficacy over the first generation, potentially offering longer-lasting treatment benefits for patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion [1] Group 2: Financial Terms - Cloudy New Horizon will pay a $7 million upfront fee and up to $24 million in reimbursable expenses, with potential development and sales milestone payments totaling up to $89 million, in addition to royalties based on net sales [1] Group 3: Strategic Expansion - This collaboration will enhance Cloudy New Horizon's late-stage product pipeline, allowing the company to expand into the ophthalmology sector [1]

Core Viewpoint - Xinda Biopharmaceutical (01801) has experienced a stock price increase of over 4%, currently trading at 84.4 HKD with a transaction volume of 330 million HKD, following the announcement of strong revenue growth in Q3 2025 [1] Financial Performance - In Q3 2025, the company reported total product revenue exceeding 3.3 billion RMB, reflecting a robust year-on-year growth of approximately 40% [1] - The growth is attributed to the dual drivers of oncology and comprehensive pipeline development [1] Product Development - As of now, the company has obtained approval for 16 products, with 2 additional products under review by the National Medical Products Administration of China [1] - Four new drug molecules have entered Phase III or pivotal clinical studies, and around 15 new drug candidates are currently in clinical research [1] Strategic Vision - 2025 marks a significant year for the company as it transitions into a new phase of dual-driven growth and global innovation [1] - The company aims to steadily progress towards its vision of becoming a world-class biopharmaceutical company [1]